NervGen

NervGen Pharma announced positive Q3 2025 results highlighting progress in the CONNECT SCI study, where NVG-291 showed clinically meaningful improvements in spinal cord injury patients versus placebo. 75% of the NVG-291 group reported global improvement compared to 33% in the placebo arm. The FDA confirmed potential regulatory pathways for NVG-291, with an End-of-Phase 2 meeting planned for early 2026. A $10.05M private placement was completed. Cash reserves stood at $11.4M. Preclinical data showed promise in hearing loss and nerve injury models.